Easterly Investment Partners LLC Trims Holdings in Pacira BioSciences, Inc. (NASDAQ:PCRX)

Easterly Investment Partners LLC reduced its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 21.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 105,651 shares of the company’s stock after selling 28,833 shares during the period. Easterly Investment Partners LLC’s holdings in Pacira BioSciences were worth $1,990,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. BNP Paribas Financial Markets grew its holdings in shares of Pacira BioSciences by 269.7% during the third quarter. BNP Paribas Financial Markets now owns 395,695 shares of the company’s stock worth $5,955,000 after buying an additional 288,662 shares during the last quarter. PDT Partners LLC acquired a new position in shares of Pacira BioSciences in the third quarter valued at approximately $3,469,000. State Street Corp raised its stake in shares of Pacira BioSciences by 5.8% during the third quarter. State Street Corp now owns 2,014,012 shares of the company’s stock worth $30,311,000 after purchasing an additional 110,162 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of Pacira BioSciences during the third quarter worth approximately $1,212,000. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Pacira BioSciences by 16.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 502,204 shares of the company’s stock worth $9,462,000 after purchasing an additional 70,307 shares during the period. 99.73% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have recently commented on PCRX shares. Barclays raised their target price on shares of Pacira BioSciences from $17.00 to $24.00 and gave the stock an “overweight” rating in a research note on Friday, February 28th. HC Wainwright increased their target price on Pacira BioSciences from $57.00 to $70.00 and gave the stock a “buy” rating in a research note on Friday, February 28th. Needham & Company LLC lifted their price target on Pacira BioSciences from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Friday, February 28th. Royal Bank of Canada reissued a “sector perform” rating and issued a $18.00 target price on shares of Pacira BioSciences in a report on Tuesday, January 14th. Finally, Truist Financial upgraded shares of Pacira BioSciences from a “sell” rating to a “hold” rating and boosted their target price for the stock from $8.00 to $25.00 in a research report on Thursday, January 30th. One research analyst has rated the stock with a sell rating, four have given a hold rating and five have assigned a buy rating to the company. According to MarketBeat, Pacira BioSciences has a consensus rating of “Hold” and an average price target of $27.22.

Pacira BioSciences Stock Performance

Shares of PCRX opened at $24.42 on Thursday. The company has a 50-day moving average of $24.65 and a two-hundred day moving average of $19.79. The stock has a market cap of $1.13 billion, a P/E ratio of -12.03 and a beta of 0.86. Pacira BioSciences, Inc. has a 12-month low of $11.16 and a 12-month high of $31.67. The company has a current ratio of 2.25, a quick ratio of 1.89 and a debt-to-equity ratio of 0.51.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.